Compare Jones Lang LaSalle Inc (JLL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Revvity Inc — how do they compare? Jones Lang LaSalle Inc trades at $363.34 (market cap $16.72B), while Revvity Inc trades at $116.47 (market cap $12.91B). The key difference: Jones Lang LaSalle Inc is the larger of the two by market cap, and Revvity Inc pays a 0.24% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| JLL | RVTY | |
|---|---|---|
Market Cap | $16.72B | $12.91B |
Sector | Real Estate | Technology |
52-Week High | $373.24 | $117.75 |
52-Week Low | $280.16 | $82.26 |
Enterprise Value | $19.48B | $15.23B |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $362.81, up 1.53% today, near its 52-week high. The stock exhibits strong technical momentum with a bullish moving average crossover and is supported by consecutive earnings beats in Q4 2025, Q1 2026, and Q2 2026. Revenue growth accelerated to $26.12 billion in 2025, with net income margin improving to 3.64%. Analyst sentiment is positive with a 54.55% buy rating and a consensus price target of $391.50, suggesting further upside potential from current levels.
The outlook for JLL is favorable, driven by robust earnings performance and solid cash flow generation. Key opportunities include continued growth in leasing and capital markets, while risks involve economic sensitivity and competitive pressures in real estate services. The stock's valuation at a P/E of 17.43 and P/S of 0.63 appears reasonable relative to growth prospects.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
